Related Experiment Videos
Severe hypertension--is there a drug of choice?
1Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, UK.
Insights
Severe hypertension management remains challenging, with current treatments failing to fully mitigate risks of stroke or myocardial infarction. More data is needed to guide drug selection for optimal patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Severe hypertension can be defined by arterial pressure, organ damage, or resistance to drug therapy, with definitions not always overlapping.
- Current treatments for severe hypertension have not eliminated the risks of stroke or myocardial infarction compared to normotensive individuals.
Purpose of the Study:
- To review the definitions and current treatment outcomes for severe hypertension.
- To highlight the need for more data on drug efficacy for specific complications like left ventricular hypertrophy and cerebral circulation issues.
Main Methods:
- Review of existing literature on severe hypertension definitions and treatment outcomes.
- Analysis of current therapeutic strategies and their limitations.
Main Results:
- Despite available drugs, current severe hypertension treatments do not normalize stroke or myocardial infarction risk.
- Data supporting drug selection for left ventricular hypertrophy, glomerular hyperfiltration, and cerebral circulation is limited.
Conclusions:
- Current drug therapy for severe hypertension is largely empirical.
- Converting enzyme inhibitors or calcium antagonists may offer advantages in treating severe hypertension.
Abstract:
Severity of hypertension may be defined in terms of the height of the arterial pressure, or the degree of organ damage present or the resistance to drug therapy. These definitions do not necessarily overlap in the individual case. A variety of drugs is now available for treatment of the severe case however defined, but results of current treatment of such cases in practice have not reduced the risk of stroke or of myocardial infarction to that of the age- and sex-matched normotensive population. Data from which to select drugs with favourable effects on left ventricular hypertrophy, glomerular hyperfiltration or the cerebral circulation are scanty and need amplification. Choice of drug therapy in current circumstances remains empirical, although there are probable advantages in the use of converting enzyme inhibitors or calcium antagonists in the treatment of severe hypertension.